Date of publication:
Reading time:
Author:
The development of modern medicine is inseparably associated with clinical trials. Owing to clinical trials new therapies can be introduced, changing patient prognosis worldwide. At Penta Hospitals, we have been actively participating in international clinical research programs for over 20 years, collaborating with leading scientific institutions and pharmaceutical companies.
Over the past two decades, our centre has taken part in numerous research projects across various fields of medicine, including urology. Owing to the dedication of our team of physicians and researchers, patients treated at Penta Hospitals gain access to innovative therapies, often before they are introduced into standard clinical practice.
One of the key figures who has helped to shape the history of clinical research at our institution is Dr. Rafał Kmieciak.
Dr. Rafał Kmieciak is a urology specialist and one of the physicians who has been involved in the development of clinical research in Poland since its early dynamic growth. For many years, he has collaborated with the Penta Hospitals team as a researcher in international clinical projects, focusing primarily on modern therapies for genitourinary diseases, including prostate cancer.
His work includes participation in numerous Phase II and Phase III clinical trials that have contributed to the development of new standards of care in urology. Due to his involvement, patients treated at our centre have access to the latest therapeutic methods and can participate in research projects conducted in accordance with the highest international standards.
One of the important projects in which our centre participated was the PREVAIL study on prostate cancer therapy.
One of the most significant research projects was the international Phase III clinical trial:
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL)
The aim of the study was to evaluate the efficacy and safety of enzalutamide compared with placebo in patients with metastatic castration-resistant prostate cancer (mCRPC) who had not previously received chemotherapy.
More than 1,700 patients from many countries participated in the study. The primary endpoints included overall survival and radiographic progression-free survival.
The study results showed that enzalutamide therapy:
These results were published in the prestigious journal New England Journal of Medicine and played a key role in expanding the indications for this drug in prostate cancer treatment.
The test substance in the PREVAIL study was enzalutamide, a modern drug belonging to the class of androgen receptor inhibitors. It blocks the signalling pathway of androgens – the hormones that stimulate the growth of prostate cancer cells.
Enzalutamide:
As a result, the therapy effectively slows disease progression and improves prognosis in patients with advanced prostate cancer.
The drug was introduced to the market under the brand name Xtandi and is currently one of the key components of treatment across multiple stages of prostate cancer.
Participation in projects such as PREVAIL demonstrates the crucial role that clinical research centres play in the advancement of modern medicine. Owing to collaboration with international sponsors and the expertise of our researchers, it is possible to implement innovative therapies that genuinely transform standards of care.
Dr. Rafał Kmieciak continues to conduct clinical trials in urology at Penta Hospitals, participating in projects focused on new therapies for prostate cancer and other urinary tract diseases.
Current research led by Dr. Rafał Kmieciak at our centre can be found at:
👉 https://badaniakliniczne.pentahospitals.pl/badania/rak-prostaty-wrazliwy-na-kastracje/
Owing to such initiatives, patients gain access to innovative therapies, and Penta Hospitals remains an important partner in the development of modern evidence-based medicine. We would like to thank Dr. Rafał Kmieciak for his many years of collaboration, trust, and contribution to the development of clinical research.
Share article:
